Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ana Marcolina

Nurse Practitioner, Gerontology Clermont, FL Nurse Practitioner

NPI 1255984175 CMS profile 10876518

1920 Don Wickham Dr Ste 100, Clermont, FL 34711

Open in the dashboard

General payments

$6,407

332 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Marcolina of Clermont, FL is reported in the CMS Open Payments database as having received $6,407 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,584 77
2024 General $1,732 87
2023 General $1,200 61
2022 General $1,080 65
2021 General $811 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Marcolina
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Ana Marcolina were reported at $1,584. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Ana Marcolina Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $811 $133 $44–$396 $132
2022 $1,080 $142 $48–$452 $149
2023 $1,200 $158 $53–$482 $160
2024 $1,732 $171 $55–$533 $164
2025 $1,584 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,367 69 payments
  2. Lilly USA, LLC $880 50 payments
  3. AbbVie, Inc. $698 44 payments
  4. AstraZeneca Pharmaceuticals LP $619 29 payments
  5. Amgen Inc. $310 19 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $299 15 payments
  7. Astellas Pharma US Inc $235 10 payments
  8. Sumitomo Pharma America, Inc. $231 10 payments
  9. Janssen Pharmaceuticals, Inc $188 8 payments
  10. Lundbeck LLC $179 8 payments
  11. Other $1,400 70 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,407 332 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $1,254 63 payments
  2. Ozempic $1,131 63 payments
  3. UBRELVY $356 20 payments
  4. JARDIANCE $339 19 payments
  5. EMGALITY $312 16 payments
  6. AIRSUPRA $312 12 payments
  7. FARXIGA $290 12 payments
  8. QULIPTA $266 17 payments
  9. MOUNJARO $261 16 payments
  10. GEMTESA $231 10 payments
  11. Other $4,140 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record